The platform features enhanced speed and digital connectivity for liquid biopsy applications, with commercial release planned for mid-2026.
Qiagen unveiled QIAsymphony Connect, the next generation of its automated nucleic acid purification platform, at the 2025 Association for Molecular Pathology annual meeting in Boston.
The first public introduction of QIAsymphony Connect builds on more than 3,000 cumulative placements at the end of 2024 of the first-generation version, with the new generation designed to support liquid biopsy applications with enhanced speed, sample traceability, and digital connectivity for labs, according to a release from the company.
“As labs face increasing pressure to process more complex samples with greater precision and speed, QIAsymphony Connect is designed to help them meet those challenges,” says Nitin Sood, senior vice president and head of product portfolio and innovation at Qiagen, in a release.
Enhanced Performance Features
QIAsymphony Connect introduces several improvements designed to enhance performance, speed, and connectivity across various diagnostic and research workflows. The platform has been made available to selected customers through an early access program ahead of full commercial release in mid-2026. The current version of QIAsymphony will remain available for purchase during the transition period.
The company is positioning the platform to address growing demand for liquid biopsy applications, which require precise sample preparation and processing capabilities.
Precision Oncology Portfolio Expansion
At the AMP meeting, Qiagen also showcased advancements across its Sample to Insight workflows, including early-access data and developments from precision oncology partnerships.
The company highlighted its QIAseq xHYB HRD Panel, which can be combined with the QIAseq xHYB CGP Panel to enable genomic profiling and homologous recombination deficiency detection within a single hybrid-capture workflow. This combined assay supports simultaneous analysis of single nucleotide variants, insertions and deletions, and copy number variants across 724 cancer-relevant genes, while also assessing key therapy biomarkers, including BRCA1/2, HRD, microsatellite instability, and tumor mutational burden.
“Our presence at AMP 2025 highlights our commitment to advancing high-growth areas of sample technologies where Qiagen is playing a leading role in supporting customers worldwide with novel liquid biopsy applications as well as working with our partners to create innovative advances in precision oncology,” says Sood in a release.
ID 255881638 © Anamaria Mejia | Dreamstime.com
